Abstract
Background: Casein Kinase 2 (CK2) is a ubiquitous cellular serine-threonine kinase
with broad spectrum of substrates. This enzyme is widely expressed in eukaryotic cells and is overexpressed
in different human cancers. Thus, the inhibition of CK2 can induce the physiological
process of apoptosis leading to tumor cell death.
Objectives: Selecting natural inhibitors toward the target enzyme using database mining.
Methods: With our continuous effort to discover new compounds with CK2 inhibitory effect, several
commercial natural databases were searched using molecular modeling approach and the selected
compounds were evaluated in vitro.
Results: Three compounds were selected as candidates and evaluated in vitro using CK2 holoenzyme,
their effect on three cancer cell lines was determined. The selected candidates were weak inhibitors
toward the target enzyme, only one compound showed moderate effect on cell viability.
Conclusion: Several natural databases were screened, compounds were selected and tested in vitro.
Despite the unexpected low inhibitory activity of the tested compounds, this study can help in directing
the search of potent CK2 inhibitors and better understand the binding requirements of the
ATP competitive inhibitors.
Keywords:
In silico screening, CK2, natural compounds, inhibitors, in vitro, cancer.
Graphical Abstract
[4]
(a)Haidar, S.; Meyers, A.; Bollacke, A.; Jose, J. Synthesis and
biological evaluation of 2,6-di(furan-3-yl)anthracene-9, 10-dione as
an inhibitor of human protein kinase CK2. Pharmazie, 2015,
70(12), 772-776..
[PMID:
26817273]
(b)Haidar, S.; Aichele, D.; Birus, R.; Hielscher, J.; Laitinen, T.; Poso, A.; Jose, J.
in vitro and in silico evaluation of bikaverin as a potent inhibitor of human protein kinase CK2., Molecules, 2019,
24(7)E1380.
[
http://dx.doi.org/10.3390/molecules24071380] [PMID:
30965682]
(c)Olgen, S.; Götz, C.; Jose, J. Synthesis and biological evaluation
of 3-(substituted-benzylidene)-1,3-dihydro-indolin derivatives as
human protein kinase CK2 and p60(c-Src) tyrosine kinase inhibitors.
Biol. Pharm. Bull., 2007, 30(4), 715-718..
[
http://dx.doi.org/10.1248/bpb.30.715] [PMID:
17409508]
(d)Jabor Gozzi, G.; Bouaziz, Z.; Winter, E.; Daflon-Yunes, N.; Aichele, D.; Nacereddine, A.; Marminon, C.; Valdameri, G.; Zeinyeh, W.; Bollacke, A.; Guillon, J.; Lacoudre, A.; Pinaud, N.; Cadena, S.M.; Jose, J.; Le Borgne, M.; Di Pietro, A. Converting potent indeno[1,2-b]indole inhibitors of protein kinase CK2 into selective inhibitors of the breast cancer resistance protein ABCG2.
J. Med. Chem., 2015,
58(1), 265-277.
[
http://dx.doi.org/10.1021/jm500943z] [PMID:
25272055]
[12]
Molecular Operating Environment (MOE), C. C. G. I., 1010
Sherbooke St. West, Suite #910, Montreal, QC, Canada, H3A 2R7;. , 2013.